CIDP with anti-neurofascin 155 (NF155) antibodies
Evidence-based neurology checklist on cidp with anti-neurofascin 155 (nf155) antibodies: Pathology NF155 are antibodies to paranodal structures They are present in 7-14% of people with CIDP HLA DRB1*15 may increase the risk of developing the antibodies Clinical pattern Clinical features Nerve…
Pathology
- NF155 are antibodies to paranodal structures
- They are present in 7-14% of people with CIDP
- HLA DRB1*15 may increase the risk of developing the antibodies
Clinical pattern
Clinical features
Nerve conduction studies (NCS)
Magnetic resonance imaging (MRI)
Other investigations
Treatment
Acronym
References
- Kuwahara M, Suzuki H, Oka N, et al. Electron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. Muscle Nerve 2017; doi: 10.1002/mus.25757 (Epub ahead of print).
- Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, Yuki N. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86:800-807.
- Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015; 2:e149.
- Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. JNNP 2017; 88:465-473.
- Doppler K, Stengel H, Appeltshauser L, et al. Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies. JNNP 2018; pii: jnnp-2018-318170 (Epub ahead of print).
- And 20 more. Subscribe to see the full list
